MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 584625 | Name: Nomifensine
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Nomifensine is a potent inhibitor of norepinephrine but has little effect on serotonin. It is unique in that it is a potent reuptake inhibitor of dopamine. Nomifensine is rapidly and completely absorbed and is widely distributed throughout the body. The major route of elimination is through the kidneys. Because of its short half-life and resultant lack of accumulation, nomifensine is usually given in divided doses. Nomifensine is a and effective antidepressant with a fairly unique pharmacological profile.

Chemical Structure

Nomifensine
Nomifensine
CAS#24526-64-5 (free base)

Theoretical Analysis

MedKoo Cat#: 584625

Name: Nomifensine

CAS#: 24526-64-5 (free base)

Chemical Formula: C16H18N2

Exact Mass: 238.1470

Molecular Weight: 238.33

Elemental Analysis: C, 80.63; H, 7.61; N, 11.75

Price and Availability

Size Price Availability Quantity
100mg USD 350.00 2 weeks
250mg USD 650.00 2 weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
24526-64-5 (free base) 32795-47-4 (maleate) 78164-59-7 (HCl)
Synonym
Nomifensine; CCRIS 9179; HSDB 7702; Linamiphen
IUPAC/Chemical Name
8-Isoquinolinamine, 1,2,3,4-tetrahydro-2-methyl-4-phenyl-
InChi Key
XXPANQJNYNUNES-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H18N2/c1-18-10-14(12-6-3-2-4-7-12)13-8-5-9-16(17)15(13)11-18/h2-9,14H,10-11,17H2,1H3
SMILES Code
NC1=CC=CC2=C1CN(C)CC2C3=CC=CC=C3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Nomifensine is a norepinephrine-dopamine reuptake inhibitor.
In vitro activity:
The effect of nomifensine on the uptake of 5-hydroxytryptamine (5-HT) and dopamine (DA) into human platelet-rich plasma has been studied. A significant inhibition of DA uptake was observed at nomifensine 10(-6) M. 5-HT uptake was significantly inhibited only at nomifensine 10(-4) M or more. Reference: Br J Clin Pharmacol. 1977;4Suppl 2(Suppl 2):159S-163S. https://pubmed.ncbi.nlm.nih.gov/911650/
In vivo activity:
In vivo extracellular recordings of locus coeruleus, ventral tegmental area and dorsal raphe nucleus neurons were obtained from male Sprague-Dawley rats. The intravenous injection of nomifensine in the locus coeruleus and ventral tegmental area yielded ED(50) values of 40 +/- 1 and 450 +/- 41 microg/kg, respectively, suggesting that nomifensine directly acted upon dopamine and norepinephrine neurons, since these values are proportional to its affinities for norepinephrine and dopamine transporters. Nomifensine (5 mg/kg/day, subcutaneous, using minipumps) potently and significantly inhibited dopamine neuronal firing in the ventral tegmental area after 2 days, with recovery to normal after the 14-day treatment due to D(2) autoreceptor desensitization. Reference: J Psychopharmacol. 2010 Aug;24(8):1223-35. https://pubmed.ncbi.nlm.nih.gov/19939862/
Solvent mg/mL mM
Solubility
DMF 25.0 104.89
DMSO 62.5 262.24
Ethanol 10.0 41.96
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 238.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Ehsanullah RS, Turner P. Effects of nomifensine in vitro on uptake of 5-hydroxytryptamine and dopamine into human platelets. Br J Clin Pharmacol. 1977;4Suppl 2(Suppl 2):159S-163S. doi: 10.1111/j.1365-2125.1977.tb05745.x. PMID: 911650; PMCID: PMC1429134. 2. Katz NS, Guiard BP, El Mansari M, Blier P. Effects of acute and sustained administration of the catecholamine reuptake inhibitor nomifensine on the firing activity of monoaminergic neurons. J Psychopharmacol. 2010 Aug;24(8):1223-35. doi: 10.1177/0269881109348178. Epub 2009 Nov 25. PMID: 19939862. 3. Robinson DL, Wightman RM. Nomifensine amplifies subsecond dopamine signals in the ventral striatum of freely-moving rats. J Neurochem. 2004 Aug;90(4):894-903. doi: 10.1111/j.1471-4159.2004.02559.x. PMID: 15287895.
In vitro protocol:
1. Ehsanullah RS, Turner P. Effects of nomifensine in vitro on uptake of 5-hydroxytryptamine and dopamine into human platelets. Br J Clin Pharmacol. 1977;4Suppl 2(Suppl 2):159S-163S. doi: 10.1111/j.1365-2125.1977.tb05745.x. PMID: 911650; PMCID: PMC1429134.
In vivo protocol:
1. Katz NS, Guiard BP, El Mansari M, Blier P. Effects of acute and sustained administration of the catecholamine reuptake inhibitor nomifensine on the firing activity of monoaminergic neurons. J Psychopharmacol. 2010 Aug;24(8):1223-35. doi: 10.1177/0269881109348178. Epub 2009 Nov 25. PMID: 19939862. 2. Robinson DL, Wightman RM. Nomifensine amplifies subsecond dopamine signals in the ventral striatum of freely-moving rats. J Neurochem. 2004 Aug;90(4):894-903. doi: 10.1111/j.1471-4159.2004.02559.x. PMID: 15287895.
1: Kang SH, Bak DH, Yeoup Chung B, Bai HW. Transformation of nomifensine using ionizing radiation and exploration of its anticancer effects in MCF-7 cells. Exp Ther Med. 2022 Apr;23(4):306. doi: 10.3892/etm.2022.11235. Epub 2022 Feb 23. PMID: 35340876; PMCID: PMC8931636. 2: Taharabaru S, Satomoto M, Tamura T, Adachi YU. Smaller effect of propofol than sevoflurane anesthesia on dopamine turnover induced by methamphetamine and nomifensine in the rat striatum: an in vivo microdialysis study. Exp Anim. 2018 May 10;67(2):147-153. doi: 10.1538/expanim.17-0092. Epub 2017 Nov 23. PMID: 29176298; PMCID: PMC5955746. 3: Ngo KT, Varner EL, Michael AC, Weber SG. Monitoring Dopamine Responses to Potassium Ion and Nomifensine by in Vivo Microdialysis with Online Liquid Chromatography at One-Minute Resolution. ACS Chem Neurosci. 2017 Feb 15;8(2):329-338. doi: 10.1021/acschemneuro.6b00383. Epub 2017 Feb 1. PMID: 28094974; PMCID: PMC5464422. 4: Shu Z, Taylor IM, Walters SH, Michael AC. Region- and domain-dependent action of nomifensine. Eur J Neurosci. 2014 Jul;40(2):2320-8. doi: 10.1111/ejn.12604. Epub 2014 Apr 26. PMID: 24766210; PMCID: PMC4107090. 5: Esumi S, Kawaski Y, Nakamoto A, Sagara H, Gomita Y, Kitamura Y, Sendo T. Differential effects of nomifensine and imipramine on motivated behavior in the runway model of intracranial self-stimulation. Eur J Pharmacol. 2013 Nov 15;720(1-3):186-191. PMID: 24436978. 6: Matthews AR, He OH, Buhusi M, Buhusi CV. Dissociation of the role of the prelimbic cortex in interval timing and resource allocation: beneficial effect of norepinephrine and dopamine reuptake inhibitor nomifensine on anxiety- inducing distraction. Front Integr Neurosci. 2012 Dec 3;6:111. doi: 10.3389/fnint.2012.00111. PMID: 23227004; PMCID: PMC3512209. 7: Poth LS, O'Connell BP, McDermott JL, Dluzen DE. Nomifensine alters sex differences in striatal dopaminergic function. Synapse. 2012 Aug;66(8):686-93. doi: 10.1002/syn.21554. Epub 2012 Apr 17. PMID: 22389194. 8: Asensi-Bernardi L, Martín-Biosca Y, Sagrado S, Medina-Hernández MJ. Electrokinetic chromatographic estimation of the enantioselective binding of nomifensine to human serum albumin and total plasma proteins. Biomed Chromatogr. 2012 Nov;26(11):1357-63. doi: 10.1002/bmc.2704. Epub 2012 Jan 25. PMID: 22275209. 9: Kitanaka J, Kitanaka N, Hall FS, Uhl GR, Asano H, Chatani R, Hayata S, Yokoyama H, Tanaka KI, Nishiyama N, Takemura M. Pretreatment with nomifensine or nomifensine analogue 4-phenyl-1,2,3,4-tetrahydroisoquinoline augments methamphetamine-induced stereotypical behavior in mice. Brain Res. 2012 Feb 23;1439:15-26. doi: 10.1016/j.brainres.2011.12.043. Epub 2011 Dec 31. PMID: 22265332; PMCID: PMC4093904. 10: Ulu ST. Spectrofluorimetric determination of nomifensine in human plasma and urine by derivatization with fluorescamine. Luminescence. 2012 Jan- Feb;27(1):80-3. doi: 10.1002/bio.1329. Epub 2011 Jun 17. PMID: 21681914. 11: Yu J, Brown DG, Burdette D. In vitro metabolism studies of nomifensine monooxygenation pathways: metabolite identification, reaction phenotyping, and bioactivation mechanism. Drug Metab Dispos. 2010 Oct;38(10):1767-78. doi: 10.1124/dmd.110.033910. Epub 2010 Jul 1. PMID: 20595377. 12: Katz NS, Guiard BP, El Mansari M, Blier P. Effects of acute and sustained administration of the catecholamine reuptake inhibitor nomifensine on the firing activity of monoaminergic neurons. J Psychopharmacol. 2010 Aug;24(8):1223-35. doi: 10.1177/0269881109348178. Epub 2009 Nov 25. PMID: 19939862. 13: Yu J, Mathisen DE, Burdette D, Brown DG, Becker C, Aharony D. Identification of multiple glutathione conjugates of 8-amino- 2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline maleate (nomifensine) in liver microsomes and hepatocyte preparations: evidence of the bioactivation of nomifensine. Drug Metab Dispos. 2010 Jan;38(1):46-60. doi: 10.1124/dmd.109.028803. PMID: 19812352. 14: Larsen TR, Rossen S, Gramsbergen JB. Dopamine release in organotypic cultures of foetal mouse mesencephalon: effects of depolarizing agents, pargyline, nomifensine, tetrodotoxin and calcium. Eur J Neurosci. 2008 Aug;28(3):569-76. doi: 10.1111/j.1460-9568.2008.06354.x. PMID: 18702728. 15: Sagara H, Kitamura Y, Sendo T, Araki H, Gomita Y. Motivational effect of nomifensine in the intracranial self-stimulation behavior using a runway method. Biol Pharm Bull. 2008 May;31(5):1036-40. doi: 10.1248/bpb.31.1036. PMID: 18451543. 16: Kunnathur V, Shemisa K, Liu B, Salvaterra TJ, Dluzen DE. Sex differences in methamphetamine-evoked striatal dopamine of mice are reversed by nomifensine. Neurotoxicol Teratol. 2006 Sep-Oct;28(5):557-62. doi: 10.1016/j.ntt.2006.07.001. Epub 2006 Jul 28. PMID: 16978834. 17: Obach RS, Dalvie DK. Metabolism of nomifensine to a dihydroisoquinolinium ion metabolite by human myeloperoxidase, hemoglobin, monoamine oxidase A, and cytochrome P450 enzymes. Drug Metab Dispos. 2006 Aug;34(8):1310-6. doi: 10.1124/dmd.106.010173. Epub 2006 May 5. PMID: 16679384. 18: Janhunen S, Tuominen RK, Ahtee L. Comparison of the effects of nicotine and epibatidine given in combination with nomifensine on rotational behaviour in rats. Neurosci Lett. 2005 Jun 24;381(3):314-9. doi: 10.1016/j.neulet.2005.02.038. PMID: 15896491. 19: Janhunen S, Tuominen RK, Piepponen TP, Ahtee L. Nicotine and epibatidine alter differently nomifensine-elevated dopamine output in the rat dorsal and ventral striatum. Eur J Pharmacol. 2005 Mar 28;511(2-3):143-50. doi: 10.1016/j.ejphar.2005.02.017. PMID: 15792782. 20: Togasaki DM, Protell P, Tan LC, Langston JW, Di Monte DA, Quik M. Dyskinesias in normal squirrel monkeys induced by nomifensine and levodopa. Neuropharmacology. 2005 Mar;48(3):398-405. doi: 10.1016/j.neuropharm.2004.10.009. Epub 2005 Jan 28. PMID: 15721172.